

Drugs and Devices Division

Drug Submission Status

Report for June 2019

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
CellChem Pharmaceuticals Inc.	CCP-Zolmitriptan	Zomig	zolmitriptan	2.5mg	tablet	02458780
CellChem Pharmaceuticals Inc.	CCP-Rizatriptan	Maxalt RPD	rizatriptan	5mg	ODT	02458764
CellChem Pharmaceuticals Inc.	CCP-Rizatriptan	Maxalt RPD	rizatriptan	10mg	ODT	02458772
Marcan Pharmaceuticals Inc.	Mar-Febuxostat	Uloric	febuxostat	80mg	tablet	02473607
Apotex Inc.	Apo-Deferasirox (Type J)	Jadenu	deferasirox	90mg	tablet	02485265
Apotex Inc.	Apo-Deferasirox (Type J)	Jadenu	deferasirox	180mg	tablet	02485273
Apotex Inc.	Apo-Deferasirox (Type J)	Jadenu	deferasirox	360mg	tablet	02485281
Apotex Inc.	Apo-Perindopril/Amlodipine	Viacoram	perindopril arginine & amlodipine besylate	3.5 mg/ 2.5 mg	uncoated tablet	02468565
Apotex Inc.	Apo-Perindopril/Amlodipine	Viacoram	perindopril arginine & amlodipine besylate	7 mg/ 5 mg	uncoated tablet	02468573
Apotex Inc.	Apo-Perindopril/Amlodipine	Viacoram	perindopril arginine & amlodipine besylate	14 mg/ 10 mg	uncoated tablet	02468581